Holen Sie sich die Stockscreener-App
7.515
2.95%
0.215
Handel nachbörslich:
7.66
0.145
+1.93%
Schlusskurs vom Vortag:
$7.30
Offen:
$7.29
24-Stunden-Volumen:
96,488
Relative Volume:
1.12
Marktkapitalisierung:
$41.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-2.4639
EPS:
-3.05
Netto-Cashflow:
$-11.88M
1W Leistung:
+14.38%
1M Leistung:
+138.57%
6M Leistung:
+142.42%
1J Leistung:
+50.30%
1-Tages-Spanne:
$7.211
$8.00
1-Wochen-Bereich:
$6.301
$8.3472
52-Wochen-Spanne:
$2.52
$8.3472
Lipocine Inc Stock (LPCN) Company Profile
Firmenname
Lipocine Inc
Sektor
Branche
Telefon
801 994 7383
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Vergleichen Sie LPCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
7.515 | 40.53M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-11 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
| 2015-06-23 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
How Lipocine Inc. stock reacts to global recession fears2026 world cup usa national team round of 16 young talents high defensive line expert forecast preview - Улправда
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154 - MSN
Lipocine price target lowered to $7 from $8 at H.C. Wainwright - MSN
Aug PreEarnings: Can Lipocine Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
Market Pulse: How Lipocine Inc. stock reacts to global recession fearsWeekly Trade Report & Long Hold Capital Preservation Tips - Улправда
Can Lipocine Inc. stock outperform in 2025 bull marketMarket Sentiment Report & Weekly High Return Stock Opportunities - Улправда
Does Lipocine Inc. stock trade at a discount to peersJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда
Return on equity % of Lipocine Inc. – BOATS:LPCN - TradingView — Track All Markets
Trend Review: Can Lipocine Inc. stock deliver consistent earnings growth2025 Valuation Update & Detailed Earnings Play Alerts - DonanımHaber
How Lipocine Inc. stock performs in high volatility marketsJuly 2025 Snapshot & Fast Gain Stock Trading Tips - DonanımHaber
Financial Review: Lipocine (NASDAQ:LPCN) vs. Astellas Pharma (OTCMKTS:ALPMY) - Defense World
Lipocine reaches 80% enrollment in postpartum depression drug trial By Investing.com - Investing.com Nigeria
Lipocine Advances Phase 3 Trial for PPD Treatment - TipRanks
Lipocine Inc Announces 80% Enrollment in PPD Phase 3 Study - TradingView — Track All Markets
Lipocine reaches 80% enrollment in postpartum depression drug trial - Investing.com India
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
Lipocine Inc. Announces Resignation of Jeffrey Fink as Director, Effective January 1, 2026 - marketscreener.com
Lipocine Earnings Notes - Trefis
Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting - Investing.com UK
EBIT per share of Lipocine Inc. – BOATS:LPCN - TradingView
Lipocine (LPCN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lipocine Inc. (LPCN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why hedge funds are buying Lipocine Inc. stockPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Can Lipocine Inc. stock sustain revenue growthJuly 2025 Weekly Recap & Community Consensus Stock Picks - newser.com
Will Lipocine Inc. stock outperform value stocksMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com
Can Lipocine Inc. stock resist sector downturnsJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
How Lipocine Inc. stock reacts to inflationary pressuresOptions Play & Free Growth Oriented Trading Recommendations - newser.com
Smart tools for monitoring Lipocine Inc.’s price actionEarnings Summary Report & Community Driven Trade Alerts - newser.com
Is Lipocine Inc. stock a safe buy before earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Lipocine reports positive safety review for PPD treatment in phase 3 trial - Investing.com Nigeria
Lipocine Announces Positive Interim Results for PPD Trial - TipRanks
[8-K] Lipocine Inc. Reports Material Event | LPCN SEC FilingForm 8-K - Stock Titan
Lipocine highlights promising interim safety profile in phase 3 trial of LPCN 1154 in postpartum depression (PPD) - MarketScreener
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - The Herald Journal
Finanzdaten der Lipocine Inc-Aktie (LPCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):